WuXi AppTec reveals the cards of the new CXO competition cycle with an annual report | Financial Report Analysis

Source: Titanium Media

On March 23, WuXi AppTec (603259.SH/02359.HK) released its 2025 annual report.

For the full year, the company achieved operating revenue of 45.46 billion yuan, up 15.84%; net profit attributable to shareholders of listed companies was 19.151 billion yuan, up sharply 102.65% year over year. The profit growth rate is more than 6 times the revenue growth rate. Net profit after deducting non-recurring items was 13.241 billion yuan, up 32.56%, clearly outperforming revenue.

Among them, peptide business revenue related to weight-loss drugs was 11.37 billion yuan, up 96% year over year. Behind this was the concentrated release of capacity utilization after the TIDES (oligonucleotide and peptide) production lines completed the capacity expansion ahead of schedule. By year-end, outstanding orders for continuing operations were 58 billion yuan, up 28.8%, providing solid support for subsequent performance.

What is even more worth reading in depth in this annual report are the industry change signals it reveals. WuXi AppTec’s strong performance is, in essence, the resonance of three factors: correctly betting on the GLP-1 peptide track; nurturing customers through the full CRDMO (contract research, process development, and commercialization manufacturing) value chain into commercialization and scale; and achieving FDA-compliant certification of scale manufacturing capacity. As a global CXO industry leader, when stripping away the appearance of short-term volatility, the annual report’s features—business-structure optimization, “efficiency strangulation,” and a global layout—provide important references for interpreting the industry’s new cycle.

Lower year-over-year cost growth, rapid commercialization and scale-up of peptide “big products”

In 2025, the explosive growth of WuXi AppTec’s peptide business, together with the scale benefits of the CRDMO model, jointly supported a double improvement in both revenue and profitability.

From the perspective of business segments, the chemical business contributes the absolute largest revenue volume. For the full year, revenue reached 36.466 billion yuan, up 25.52%, accounting for more than 80% of total revenue. The core driver of growth in this segment comes from the large-scale ramp-up of the TIDES business. The main driving force is the production of peptide API for weight-loss drugs and diabetes drugs represented by GLP-1.

Benefiting from the gradual ramp-up of newly added capacity in 2024, together with the continued fermentation of the global weight-loss-drug R&D boom, TIDES business revenue in 2025 nearly doubled year over year to 11.37 billion yuan. Outstanding orders grew 20.2% year over year, and the number of customers served and the number of molecules served increased by 25% and 45% respectively year over year.

Behind this growth rate is structural demand brought about by the market explosion of GLP-1-related drugs (such as semaglutide and tirzepatide, etc.). This area is also the biggest single therapeutic field “boom” in global pharmaceutical history over the past decade.

Meanwhile, the small-molecule D&M (process development and manufacturing) business maintained steady growth. Revenue was 19.2 billion yuan, up 11.4%. The pipeline added 839 molecules during the year, bringing the total to 3,452 molecules. Commercialized and Phase III clinical projects totaled 174 (with 22 added during the year). The proportion of later-stage projects continued to rise, becoming an important support for improving profitability.

The testing business and the biology business show a “more revenue but not more profit” profile. For the full year, revenue was 4.042 billion yuan and 2.677 billion yuan respectively, up 4.69% and 5.24% year over year, but gross margin fell by 6.32 and 3.04 percentage points respectively year over year. Among them, gross profit for the testing business fell 36.29% year over year to 1.182 billion yuan. Although in both major businesses, the revenue share of newly added molecule businesses exceeded 30%, and new customer growth was significant in areas such as nucleic-acid-type and conjugated-antibody-type fields, causing the business mix to tilt toward higher value-added areas, intensified market competition brought visible pricing pressure, which in turn affected the level of profitability.

Optimization of the business structure directly translated into profitability. In 2025, the company’s gross margin rose from approximately 41.48% in the prior year to 47.64%, increasing by more than 6 percentage points within one year. The weighted average return on net assets reached 28.56%, up 11.78 percentage points from the prior year.

The core logic behind the improvement in profitability is the “scissor spread” of “high revenue growth + low cost growth.” The company’s operating revenue grew 15.84% year over year, but operating costs grew only 3.64% year over year. Cost growth was less than one quarter of revenue growth. In essence, this result comes from synchronized optimization of capacity utilization and operating efficiency after the share of late-stage clinical and commercialization projects increased.

Continued expansion of capacity scale further amplified profit elasticity. As of September 2025, the total volume of peptide solid-phase synthesis reaction tanks exceeded 100,000 liters, and the construction task for the Taixing base was completed ahead of schedule. The total volume of small-molecule API reaction tanks exceeded 4,000 thousand liters. The API bases in Changzhou, Taixing, and Jinshan all passed FDA on-site inspections with zero defects. With large-scale capacity construction completed in the earlier stage, new orders ramped up on the basis of existing capacity, and marginal costs were significantly diluted—becoming a key driver for releasing profit elasticity.

It should be noted that the contribution of non-recurring gains and losses to net profit was significant. In 2025, WuXi AppTec’s non-recurring gains and losses were 5.91 billion yuan, mainly from gains from selling equity in associates, divesting part of its business and financial assets, and gains from changes in the fair value of financial assets.

For shareholder returns, in 2025 the company accumulated cash dividends of 6.755 billion yuan. Combined with a 2.0 billion yuan share repurchase and cancellation, the total return to shareholders was 8.755 billion yuan, accounting for 45.72% of attributable net profit. The proposed profit distribution for the year is a dividend of 15.7927 yuan (tax included) per 10 shares. Together with the interim and special dividends, the total dividends per 10 shares for the full year are 22.7927 yuan.

Industry changes at a glance: triple adjustments in demand, competition, and layout

The annual report data from WuXi AppTec also reveals the structural changes taking place in the CXO industry.

On the demand-structure front, new molecular types have become the core driver of growth, while growth in the traditional small-molecule business has slowed.

As R&D of traditional small-molecule drugs enters a bottleneck period and R&D returns decline, pharmaceutical companies gradually shift resources toward emerging areas such as peptides, oligonucleotides, and conjugated drugs. Especially for unmet medical needs such as obesity and rare diseases, direct demand is driving a surge in related CXO service demand.

The continued commercialization scale-up of peptide “big products” is driving growth in CDMO peptide orders. Domestic CDMO companies have sufficient capacity reserves and ample outstanding orders, leading to rapid revenue growth in relevant areas. The boost in outsourced orders in the GLP-1 and ADC sectors also helps related CDMO companies see marginal improvement in year-over-year revenue growth rates.

According to a Frost&Sullivan report forecast in September 2025, global pharmaceutical R&D spending will grow from 277.6 billion USD in 2024 to 373.1 billion USD in 2029, with a compound annual growth rate of 6.1%. The proportion of global pharmaceutical R&D spending outsourced will increase from 51.9% in 2024 to 60% in 2029.

Behind this growth trend are multiple factors working together, including the intensifying aging of the global population, the release of unmet medical needs, and the increased outsourcing proportion of R&D by large pharmaceutical companies as well as the rise of small and mid-sized innovative drug companies.

At the same time, the report forecasts that the global pharmaceutical R&D outsourcing services market (excluding large-molecule and CGT CDMO) will grow from 136.5 billion USD in 2024 to 239.5 billion USD in 2029, with a compound annual growth rate of about 11.9%, significantly higher than the industry average. Among them, the global peptide CDMO market size is 4.4 billion USD in 2025, and is expected to grow to 7.9 billion USD by 2030.

On the competitive-logic front, integrated capabilities have become a core competitive moat, and the industry has shifted from scale competition to efficiency competition.

In the early years of the CXO industry, the core of competition was capacity and cost. But as pharmaceutical companies’ R&D needs become more complex, service at a single link can no longer meet demand. A model providing end-to-end “research-development-production” capabilities has gradually become the mainstream.

In 2025, WuXi AppTec’s small-molecule drug discovery business delivered 420,000 new compounds in total throughout the year, converted 310 molecules from R to D, and formed a closed loop of upstream customer funneling and downstream monetization. The barrier of this model lies in long-term accumulated technical capabilities, customer resources, and capacity layout. It is difficult for small and mid-sized enterprises to replicate it in the short term, making an increase in industry concentration an inevitable trend.

Under the CRDMO model, early-stage projects (R stage) have relatively low profit margins. As projects move forward to Phase III clinical and commercialization (D&M stage), capacity utilization improves and fixed-cost amortization begins, causing a significant expansion in marginal profit margins. In essence, after “cultivating” early customers into the commercialization stage, profitability upgrades naturally follow.

On the global layout front, regional demand divergence is intensifying, and compliance and collaboration have become key.

In 2025, revenue contributed by WuXi AppTec’s U.S. customers was 31.25 billion yuan, up 34.3%, and its share of total revenue further expanded. Revenue from European customers was 4.82 billion yuan, down 4% year over year. Revenue from Chinese customers was 5.47 billion yuan, down 3.5% year over year. Despite external environmental changes such as the 2024 biosafety law and the mid-2025 tariff conflict between China and the U.S., the company has not been included in the biosafety law and the 1260H list, and the overseas business growth rate remains strong.

Behind these figures are two layers of logic. On the one hand, the explosion of GLP-1 and other innovative drugs’ commercialization outsourcing demand from major U.S. customers is the core source of the company’s growth. This also means that overall growth is becoming increasingly dependent on the U.S. market, especially a small number of top customers. If the main customers’ product pipeline or capacity strategy changes, the transmission effect will be relatively obvious. On the other hand, the mild decline in revenue in China and Europe reflects the weakness of regional R&D outsourcing demand during the global bio-pharmaceutical investment and financing contraction cycle. It is an indisputable fact that many domestic Biotech companies have cut early-stage R&D outsourcing under financing pressure. How to maintain growth resilience without over-relying on a single U.S. market while waiting for the China market to recover will be the company’s longer-cycle strategic proposition.

CITIC Securities’ analysis points out that although recent geopolitical risks have reset expectations for rate cuts and heightened risk-avoidance sentiment, WuXi AppTec’s continuously increasing share of CMO (contract manufacturing organization) business is steadily reducing its sensitivity to marginal changes in interest rates and biotech financing. (Text by: Company Observation; Author: Cao Qian; Editor: Cao Shengyuan)

Special statement: The information above only represents the author’s personal views or positions and does not represent the views or positions of Sina Finance Headline. If, due to the content of the work, copyright, or other issues, it is necessary to contact Sina Finance Headline, please do so within 30 days after the publication of the content above.

Massive information, precise insights—right here in the Sina Finance APP